News stories about Aldeyra Therapeutics (NASDAQ:ALDX) have been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aldeyra Therapeutics earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 48.0917399121012 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Several equities research analysts have issued reports on the stock. Zacks Investment Research cut shares of Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. HC Wainwright set a $18.00 price objective on shares of Aldeyra Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. ValuEngine cut shares of Aldeyra Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 6th. Cowen reissued an “outperform” rating and issued a $14.00 price objective (up from $9.00) on shares of Aldeyra Therapeutics in a research report on Thursday, September 14th. Finally, Cantor Fitzgerald assumed coverage on shares of Aldeyra Therapeutics in a research report on Tuesday, October 24th. They issued an “overweight” rating and a $22.00 price objective for the company. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $17.29.
Shares of Aldeyra Therapeutics (ALDX) opened at $6.45 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 20.35 and a quick ratio of 20.35. Aldeyra Therapeutics has a 52-week low of $3.80 and a 52-week high of $11.90.
In other Aldeyra Therapeutics news, major shareholder Life Sciences Maste Perceptive purchased 200,000 shares of the stock in a transaction dated Tuesday, September 19th. The stock was purchased at an average price of $7.25 per share, with a total value of $1,450,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 19.04% of the stock is currently owned by corporate insiders.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.